Valuation: AstraZeneca PLC

Market Cap 290B 446,134B 260B 239B 217B 405B 27,543B 412B 2,850B 1,144B 14,488B 1,089B 1,065B 45,691B P/E 2026 *
24.5x
P/E 2027 * 20.9x
Enterprise Value 311B 477,924B 278B 256B 232B 434B 29,505B 442B 3,053B 1,225B 15,521B 1,166B 1,141B 48,947B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 4.5x
Free-Float
96.62%
Yield 2026 *
1.79%
Yield 2027 * 1.9%
1 day+7.48%
1 week+9.15%
Current month+18.08%
1 month+18.08%
3 months+15.22%
6 months+9.50%
Current year+9.46%
1 week 70,075
Extreme 70075
77,950
1 month 62,475
Extreme 62475
77,950
Current year 60,650
Extreme 60650
80,275
1 year 60,650
Extreme 60650
80,275
3 years 24,288
Extreme 24288
80,275
5 years 5,438.5
Extreme 5438.5
80,275
10 years 214.5
Extreme 214.5
80,275
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+7.48%+9.15% - - 271B
+3.19%+11.31%+67.86%+150.58% 1,224B
-0.73%+3.56%+44.51%+85.81% 662B
+1.41%+3.24%+29.22%+107.83% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.18%+2.93%+73.30%+45.62% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.15%+6.09%+59.59%+77.06% 249B
+3.06%+9.38%+44.11%+119.47% 205B
Average +2.30%+5.61%+46.59%+83.14% 464.09B
Weighted average by Cap. +1.55%+6.35%+50.91%+98.22%

Financials

2026 *2027 *
Net sales 63.32B 97,391B 56.71B 52.17B 47.27B 88.35B 6,013B 90.01B 622B 250B 3,163B 238B 233B 9,974B 67.37B 103,614B 60.34B 55.5B 50.29B 94B 6,397B 95.76B 662B 266B 3,365B 253B 247B 10,612B
Net income 11.75B 18,067B 10.52B 9.68B 8.77B 16.39B 1,115B 16.7B 115B 46.33B 587B 44.09B 43.15B 1,850B 13.63B 20,968B 12.21B 11.23B 10.18B 19.02B 1,294B 19.38B 134B 53.77B 681B 51.16B 50.08B 2,147B
Net Debt 20.67B 31,790B 18.51B 17.03B 15.43B 28.84B 1,963B 29.38B 203B 81.52B 1,032B 77.57B 75.92B 3,256B 13.23B 20,349B 11.85B 10.9B 9.88B 18.46B 1,256B 18.81B 130B 52.18B 661B 49.65B 48.6B 2,084B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-10-30 ARS 77,225.00 +7.48% 3,130
26-10-29 ARS 71,850.00 +2.46% 670
26-10-28 ARS 70,125.00 -0.14% 1,098
26-10-27 ARS 70,225.00 -2.40% 1,297
26-10-26 ARS 71,950.00 +1.70% 913
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
187.02USD
Average target price
210.05USD
Spread / Average Target
+12.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC